€0.39
+0.00 (+0.26%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALCOX.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 5 observational
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)NCT03009799Viral eradication time NCX 4240 versus PlaceboRandomized · Double-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study stopped following management decision | Drug: Iota-Carrageenan, Carmellose | Adenoviral Conjunctivitis | 0 | Aug 2017 | 2017-05-10 |
| ADenoVirus Initiative Study in Epidemiology in ItalyNCT03055065observationalFrequency of patients with adenovirus conjunctivitis | — | Completed | — | Viral Conjunctivitis | 241 | Oct 2015actual | 2017-02-16 |
| ADenoVirus Initiative Study in Epidemiology in SpainNCT02254330observationalFrequency of patients with adenovirus conjunctivitis | — | Completed | — | Viral Conjunctivitis | 386 | Aug 2015actual | 2017-01-10 |
| ADenoVirus Initiative Study in Epidemiology in GermanyNCT02054273observationalFrequency of patients with adenovirus conjunctivitis | — | Completed | — | Viral Conjunctivitis | 240 | Jun 2015actual | 2017-01-11 |
| ADenoVirus Initiative Study in Epidemiology in UKNCT02112773observationalFrequency of patients with adenovirus conjunctivitis | — | Completed | — | Viral Conjunctivitis | 31 | Jun 2015actual | 2015-10-20 |
| ADenoVirus Initiative Study in Epidemiology in FranceNCT02054234observationalFrequency of patients with adenovirus conjunctivitis | — | Completed | — | Viral Conjunctivitis | 357 | Dec 2014actual | 2015-02-10 |
| Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in MaleNCT01404598Part 1 : PK profile in plasma, saliva and urine : determination of nitrate levels.Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: naproxcinod 750 bid, naproxcinod 3000 mg od, naproxen 500 mg bid | Pharmacokinetics | 24 | Feb 2010actual | 2011-08-11 |
| Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of FurosemideNCT00909519To evaluate the effect of naproxcinod on the renal function when co-administered with furosemide in comparison to naproxen and placeboRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: naproxcinod, Naproxen, placebo, furosemide | Renal Hemodynamics | 31 | Apr 2009actual | 2011-06-17 |
| Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the KneeNCT00504127To show that both doses of Naproxcinod (375 mg twice daily [bid] and 750 mg bid) were superior to placebo in relieving osteoarthritis (OA) signs and symptoms in subjects with OA of the knee at Week 13.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Naproxcinod 375 mg bid, Naproxcinod 750 mg bid, Naproxen 500 mg bid, placebo | Osteoarthritis | 1,020 | Dec 2008actual | 2011-06-17 |
| Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the HipNCT00541489The primary objective of this study is to show that Naproxcinod is superior to placebo in relieving OA signs and symptoms in subjects with OA of the hipRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Naproxcinod, Naproxen, Placebo | Osteoarthritis, Osteoarthritis, Hip | 800 | Sep 2008actual | 2009-02-20 |
| To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential HypertensionNCT00662896To characterize the 24-hour arterial blood pressure profile of naproxcinod, compared to naproxen as measured by ABPM, through assessing the mean change from baseline in patients with OA and controlled essential hypertension.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid | Osteoarthritis, Hypertension | 300 | Sep 2008actual | 2011-06-17 |
| A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal FunctionNCT00674856To assess differences in the plasma pharmacokinetics profile of naproxcinod and naproxen (total and unbound) between renal impaired patients and healthy subjects.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: naproxcinod | Renal Failure | 32 | Sep 2008actual | 2009-01-28 |
| A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood PressureNCT00662610To characterize the 24-hour arterial blood pressure profile of different doses of naproxcinod, as measured by ABPM after each treatment period, compared to different doses of naproxen after three 3-week forced titration.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid | Osteoarthritis, Hypertension | 120 | Aug 2008actual | 2011-06-17 |
| A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy SubjectsNCT00621881To assess the pharmacokinetics of naproxcinod and its metabolites after repeated 750 mg bid oral administration of naproxcinod in hepatic impaired patient in comparison with matching healthy subjectsNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: naproxcinod | Liver Disease | 24 | Apr 2008actual | 2011-06-17 |
| Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the KneeNCT00542555The primary objective of this study is to show that naproxcinod is superior to placebo in relieving OA signs and symptoms in subjects with OA of the knee at 13 weeks and to collect long term safety dataRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Naproxcinod 375 mg, Naproxen, Naproxcinod 750 mg | Osteoarthritis | 918 | — | 2011-06-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19